2021
Seizure Prophylaxis After Spontaneous Intracerebral Hemorrhage
Jones F, Sanches P, Smith J, Zafar S, Blacker D, Hsu J, Schwamm L, Newhouse J, Westover M, Moura L. Seizure Prophylaxis After Spontaneous Intracerebral Hemorrhage. JAMA Neurology 2021, 78: 1128-1136. PMID: 34309642, PMCID: PMC8314179, DOI: 10.1001/jamaneurol.2021.2249.Peer-Reviewed Original ResearchMeSH KeywordsAged, 80 and overAnticonvulsantsCerebral HemorrhageDecision Support Systems, ClinicalDecision Support TechniquesFemaleHumansMaleMiddle AgedSeizuresConceptsEarly seizure prophylaxisSpontaneous intracerebral hemorrhageAdverse drug reactionsRisk-guided strategyLate seizuresLong-term therapyHigh riskSeizure prophylaxisPrimary prophylaxisIntracerebral hemorrhageLower riskLong-term adverse drug reactionsLow-risk patientsShort-term prophylaxisDecision analytical modelSecondary therapyProphylaxis strategiesDrug reactionsProphylaxisMAIN OUTCOMESeizuresPatientsClinical decisionTherapyAverage risk
2014
Door-to-Needle Times for Tissue Plasminogen Activator Administration and Clinical Outcomes in Acute Ischemic Stroke Before and After a Quality Improvement Initiative
Fonarow G, Zhao X, Smith E, Saver J, Reeves M, Bhatt D, Xian Y, Hernandez A, Peterson E, Schwamm L. Door-to-Needle Times for Tissue Plasminogen Activator Administration and Clinical Outcomes in Acute Ischemic Stroke Before and After a Quality Improvement Initiative. JAMA 2014, 311: 1632-1640. PMID: 24756513, DOI: 10.1001/jama.2014.3203.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBrain IschemiaDecision Support Systems, ClinicalFemaleFibrinolytic AgentsGuideline AdherenceHospital MortalityHospitalsHumansIntracranial HemorrhagesMaleMiddle AgedPatient DischargeQuality ImprovementRegistriesStrokeThrombolytic TherapyTissue Plasminogen ActivatorTreatment OutcomeConceptsAcute ischemic strokeQuality improvement initiativesTissue plasminogen activatorNational quality improvement initiativeSymptomatic intracranial hemorrhageDTN timeTPA administrationIntracranial hemorrhagePostintervention periodIschemic strokeNeedle timeClinical outcomesPreintervention periodImprovement initiativesHospital risk-adjusted mortalityIntravenous tissue plasminogen activatorTissue plasminogen activator administrationMedian DTN timePercentage of patientsProportion of patientsClinical decision support toolRisk-adjusted mortalityGuidelines-StrokeHospital mortalityYear preintervention